Commonwealth Numbered Regulations

1985 No. 320 NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS (AMENDMENT) - SCHEDULE 4

                                   SCHEDULE 4                     Regulation
8
AMENDMENTS OF SCHEDULE 5 TO THE
NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS 1. Omit item 5,
substitute the following item:
       "5 'ALFARE'                           With the written authority of
the
Secretary -
Biliary atresia
Cystic fibrosis
Enterokinase deficiency
Intolerance to both milk protein
and soya protein
Severe diarrhoea of greater than
two weeks duration in infants
under the age of 4 months". 2. Omit item 10. 3. Omit item 13. 4. Omit item 26,
substitute the following item:
       "26 (1) Calcium Carbonate, B.P.          Hypocalcaemia

           (2)  Calcium Carbonate, B.P., with   Osteoporosis

                   Calcium Lactate-Gluconate    Proven malabsorption".
5. Omit item 27, substitute the following item:
       "27 Calcium Folinate                     Antidote to folic acid

antagonists". 6. Omit item 28. 7. Omit item 29, substitute the following item:
       "29 Captopril                        Moderate or servere hypertension

For the continuing treatmen t of
severe refractory cardiac failure
where treatment with captopril
was initiated in a hospital". 8. Omit item 34. 9. Omit item 38. 10. Omit item
43, substitute the following item:
       "43 (1) Chlorpromazine Elixir, B.P.      Chorea


(2) Chlorpromazine Injection, B.P. Hyperactive states of organic or
toxic delirium
           (3)  Chlorpromazine Suppositories,   Major psychoses including -

                B.P.                              Major organic psychoses

including arteriopathic
           (4)  Chlorpromazine Tablets, B.P.        dementia

Manic depressive disorder manic
phase
Paranoid states
Schizophrenia
Senile dementia
Malignant neoplasia (late stage)
Radiation sickness
Severe conduct disorders in
patients under the age of 16
years". 11. Omit item 48, substitute the following item:
       "48 (1) Cloxacillin Capsules, B.P.     Infections due to the presence
of

(2) Cloxacillin Sodium, B.P., with penicillin-resistant
staphylococci
                 Purified Water, B.P.         Osteomyelitis".
12. Omit item 54, substitute the following item:
       "54 Dantrolene Sodium                  Treatment of chronic
spasticity". 13. Omit item 56, substitute the following item:
       "56 Demeclocycline Capsules, B.P.      Syndrome of inappropriate

antidiuretic hormone secretion,
caused otherwise than by
treatment with a drug". 14. Omit item 60, substitute the following item:

"60 (1) Dextromoramide Tablets, B.P. Disabling pain associated
with proven malignant
           (2)  Dextromoramide Tartrate, B.P.   neoplasia".
15. Omit item 67. 16. Omit item 73, substitute the following item:
       "73 Etretinate                        With the written authority of
the
Secretary -
Treatment initiated in a hospital
of -
Chronic disfiguring discoid
lupus erythematosus
Darier's disease
Erythrokeratoderma
Pityriasis rubra pilaris
Severe congenital ichthyosis
(lamellar, bullous and sex
linked)
Severe intractable psoriasis
Severe palmo-plantar keratoderma
For the continuing treatment of a
patient who has already
received, for more than 6
months, therapy with etretinate
for a condition listed above". 17. Omit item 74, substitute the following
item:
       "74 (1)  Flucloxacillin Capsules, B.P.    Infections due to the
presence
          (2) Flucloxacillin Sodium, B.P.,        of penicillin-resistant

             with Purified Water, B.P.            staphylococci
Osteomyelitis". 18. Omit item 77, substitute the following item:
       "77 (1)  Fluphenazine Decanoate           Chorea

                 Injection, B.P.                 Hyperactive states of

organic or toxic delirium

(2) Fluphenazine Hydrochloride,
                 B.P.                         Major psychoses including -

           (3)  Fluphenazine Tablets, B.P.     Major organic psychoses
including
arteriopathic dementia
Manic depressive disorder
manic phase
Paranoid states
Schizophrenia
Senile dementia
Malignant neoplasia (late
stage) Radiation sickness". 19. Omit item 80, substitute the following item:
    "80 Fusidic Acid, B.P.                       For use in combination with

another antibiotic in the
treatment of serious
staphylococcal infections
confirmed by bacteriological
evidence". 20. Omit item 85, substitute the following item:
    "85   (1) Haloperidol, B.P.                  Chorea

          (2) Haloperidol Tablets, B.P.          Hyperactive states of
organic
or toxic delirium
Major psychoses including
Major organic psychoses
including arteriopathic
dementia
Manic depressive disorder
manic phase
Paranoid states
Schizophrenia
Senile dementia
Malignant neoplasia (late
stage) Radiation sickness". 21. Omit item 93, substitute the following item:
    "93   (1) 'KETOVITE' Liquid                  With the written authority
of
the Secretary -
          (2) 'KETOVITE' Tablets                  Chronic cholestasis

Galactosaemia
Persistent monosaccharide
intolerance
Phenylketonuria
Tyrosinosis (hereditary)
Use in association with a
ketogenic diet". 22. Omit item 98, substitute the following item:
    "98   (1) Medroxyprogesterone Acetate,        Breast cancer

          B.P., Injection, 50 mg in 1 mL          Endometrial cancer

Renal cell cancer".

(2) Medroxyprogesterone Acetate,
B.P., Injection, 500 mg in 2.5
mL

(3) Medroxyprogesterone Acetate,
B.P., Tablets, 100 mg 23. Omit item 104. 24. Omit item 105. 25. Omit item 110,
substitute the following item:
    "110 Metronidazole, B.P.                      Prophylaxis in large bowel

surgery
Treatment in a hospital of
acute anaerobic sepsis". 26. Omit item 115, substitute the following item:
    "115  (1) Nalidixic Acid Mixture, B.P.        For use as a urinary

          (2) Nalidixic Acid Tablets, B.P.          antiseptic in patients
with
neurogenic bladder
Urinary tract infections
where current clinical and
bacteriological evidence
confirm that nalidixic
acid is the most
appropriate therapeutic
agent". 27. Omit item 119. 28. Omit item 120. 29. Omit item 129, substitute
the following item:
    "129  (1) Penicillamine, B.P.                 Acute heavy metal
intoxication
          (2) Penicillamine Tablets, B.P.         Cystinosis

Cystinuria with calculus
formation Haemoglobinuria,
paroxysmal cold Severe
rheumatoid arthritis
Wilson's disease
(hepatolenticular
degeneration)". 30. Omit item 131, substitute the following item:
    "131 Pericyazine                              Chorea

Hyperactive states of organic
or toxic delirium
Major psychoses including -
Major organic psychoses
including arteriophatic
dementia
Manic depressive disorder -
manic phase
Paranoid states
Schizophrenia
Senile dementia
Malignant neoplasia (late
stage) Radiation sickness
Severe conduct disorders in
patients under the age of 16
years". 31. After item 131 insert the following item:
    "131A Pethidine Tablets, B.P.                 With the written authority
of
the Secretary -
Disabling pain associated
with proven malignant
neoplasia". 32. Omit item 132, substitute the following item:
    "132  Phenelzine Tablets, B.P.                Depressive illness
resistant
to treatment with either
tricyclic antidepressants
or electroconvulsive
therapy Phobic states". 33. Omit item 142. 34. Omit item 147. 35. Omit item
148, substitute the following item:
    "148  Propantheline Tablets, B.P.             Chronic neurogenic

incontinence of urine". 36. Omit item 152, substitute the following item:
     "152 Rifampicin, B.P.                        Prophylaxis of
meningococcal
disease in close contacts
and carriers
With the written authority of
the Secretary -
Leprosy in adults". 37. After item 153 insert the following item:
    "153A Socium Acid Phosphate, B.P.,            With the written authority
of
the Secretary -
              Compound Effervescent Tablets       Familial hypophosphataemia

Hypercalcaemia
Vitamin D-resistant rickets". 38. Omit item 156, substitute the following
item:
     "156 Sodium Fusidate, B.P.                   For use in combination with

another antibiotic in the
treatment of serious
staphylococcal infections
confirmed by bacteriological
evidence". 39. Omit item 167, substitute the following item:
    "167  Tetrabenazine                           Chorea not adequately

controlled by other drug
therapy". 40. Omit item 170, substitute the following item:
    "170  (1) Thioridazine Hydrochloride,         Chorea

          B.P.                                    Hyperactive states of
organic
or toxic delirium
     (2)  Thioridazine Tablets, B.P.              Major psychoses including

Major organic psychoses
including arteriopathic
dementia
Manic depressive disorder
manic phase
Paranoid states
Schizophrenia
Senile dementia
Malignant neoplasia (late
stage)
Radiation sickness
Severe conduct disorders in
patients under the age of 16
years". 41. Omit item 172, substitute the following item:
    "172  Tobramycin Injection, B.P.              Infections where positive

bacteriological
evidence confirms that
tobramycin is the most
appropriate antibiotic
Septicaemia, suspected or
proven". 42. Omit item 174, substitute the following item:
    "174  Tranexamic Acid Tablets, B.P.           Hereditary angio-oedema".
43. Omit item 175, substitute the following item:
    "175  Tranylcypromine Tablets, B.P.           Depressive illness
resistant
to treatment with either
tricyclic antidepressants
or electroconvulsive
therapy Phobic states". 44. Omit item 177, substitute the following item:
    "177  (1) Trifluoperazine                     Chorea

              Hydrochloride, B.P.                 Hyperactive states of
organic
or toxic delirium

(2) Trifluoperazine
          Hydrochloride Tablets,                  Major psychoses including

          B.P.                                     Major organic psychoses

including arteriopathic
dementia
Manic depressive disorder
manic phase
Paranoid states
Schizophrenia
Senile dementia
Malignant neoplasia (late
stag)
Radiation sickness
Severe conduct disorders in
patients under the age of
16 years". 45. Omit item 180.